Mobile

A Randomized, Open-label, Multi-center Trial Investigating Zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in Combination with Chemo-Radiation in Stage IIIA-IIIB Non Small Cell Lung Cancer...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-004945-40

A Randomized, Open-label, Multi-center Trial Investigating Zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in Combination with Chemo-Radiation in Stage IIIA-IIIB Non Small Cell Lung Cancer Patients

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate that treatment with zalutumumab in combination with chemo-radiation is superior to chemo-radiation alone in terms of progression free survival in treatment naïve stage IIIA–IIIB NSCLC patients.

Critère d'inclusion

  • Stage IIIA-IIIB Non Small Cell Lung Cancer

Liens